Biologic facts
BrandAvastin (Bevacizumab)
6 bevacizumab biosimilars from 6 makers are licensed. The 12-year reference exclusivity date of 02/2016 is an estimate from first approval; the Purple Book does not list patents, which can protect a biologic longer.
Avastin was first approved by the FDA in 2004; the application holder is Genentech, Inc.
The most recent FDA recall on record is a Class II recall dated 09/22/2025.
Holder Genentech, Inc.Approved 2004
01Exclusivity
When biosimilar competition can legally begin. The Purple Book lists reference exclusivity but not patents, which can protect a biologic longer.
- Patents
- Not listed in the Purple Book Purple Book
- Reference exclusivity
- 02/201612-year estimate from first approval Purple Book
02Competition
- Biosimilars
- 6 biosimilars from 6 makers Purple Book
Every makerEach licensed product and biosimilar maker.
PrescribersWho prescribes it, from Medicare data.
Spend and safetyMedicare Part B spend and safety reports.
Available in the full Avastin profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- Latest recall
- 09/22/2025Class II, Bevacizumab 1.75 Mg/0.07 Ml - 0.25 Ml Sy..., Rc Outsourcing, LLC FDA enforcement
04Product
- Application holder
- Genentech, Inc. Purple Book
- First approved
- 2004 Purple Book
- Other brand names
- Lytenava
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.